We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Rescinds Emergency Authorization of GlaxoSmithKline’s and Vir Biotechnology’s COVID-19 Treatment
FDA Rescinds Emergency Authorization of GlaxoSmithKline’s and Vir Biotechnology’s COVID-19 Treatment
The FDA has withdrawn its Emergency Use Authorization (EUA) for the GlaxoSmithKline and Vir Biotechnology COVID-19 monoclonal antibody treatment sotrovimab based on data indicating that it isn’t effective against the Omicron BA.2 subvariant.